Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-iFAP
- Development stage
- Unknown
- Lead developer
- Instituto Nacional de Investigaciones Nucleares
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
99mTc-iFAP is a small molecule radiopharmaceutical designed for Single Photon Emission Computed Tomography (SPECT) imaging of the tumor microenvironment and cardiac remodeling. It consists of a fibroblast activation protein (FAP) inhibitor based on a boronic acid structure, labeled with the radioisotope technetium-99m (99mTc) via a hydrazinonicotinamide (HYNIC) chelator. The agent specifically targets Fibroblast Activation Protein (FAP), which is overexpressed on cancer-associated fibroblasts (CAFs) in the stroma of most human epithelial tumors and on activated fibroblasts in the heart following myocardial infarction. Developed by the Instituto Nacional De Investigaciones Nucleares (ININ) in collaboration with academic institutions like Yale University, 99mTc-iFAP is being evaluated for its ability to detect primary tumor lesions, lymph node metastases, and to quantify active cardiac remodeling post-ischemia reperfusion injury.
- Other names
- 99mTc-((R)-1-((6-hydrazinylnicotinoyl)-D-alanyl) pyrrolidin-2-yl) boronic acid
02
Targets
FAP (Fibroblast activation protein alpha)PREP (Prolyl Oligopeptidase)
Beyond the preview
Go deeper on 99mTc-iFAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-iFAP.